In contrast, a meta-analysis conducted by Zhang et al. reported significantly shorter OS rates and advanced tumor stages in patients with positive TIM-3 expression in various solid tumors including colon cancer, gastric cancer, renal cell carcinoma and non-small cell lung cancer (NSCLC) [28]. This evidence concerns the gene HAVCR2 and hereditary clear cell renal cell carcinoma.